| dbo:abstract |
Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites. Development was discontinued in 2009. (en) Satavaptan (Nome in codice dello sviluppo SR121463, ex marchio provvisorio Aquilda) è un antagonista del recettore della vasopressina-2 che è stato scoperto dalla Sanofi-Aventis ed era in fase di sviluppo per il trattamento dell'iponatremia. È stato anche studiato per il trattamento dell'ascite. Lo sviluppo è stato interrotto nel 2009. (it) |
| dbo:casNumber |
185913-78-4 |
| dbo:fdaUniiCode |
AJS8S3P31H |
| dbo:pubchem |
9810773 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Satavaptan_structure.svg?width=300 |
| dbo:wikiPageID |
18065584 (xsd:integer) |
| dbo:wikiPageLength |
3080 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
997782188 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Vasopressin_receptor_antagonist dbr:Hyponatremia dbc:Diuretics dbc:Tert-butyl_compounds dbr:International_Nonproprietary_Name dbr:Ascites dbc:Vasopressin_receptor_antagonists dbr:Sanofi-Aventis |
| dbp:atcPrefix |
none (en) |
| dbp:c |
33 (xsd:integer) |
| dbp:casNumber |
185913 (xsd:integer) |
| dbp:chemspiderid |
32699105 (xsd:integer) |
| dbp:h |
45 (xsd:integer) |
| dbp:iupacName |
N--4-{[-5'-ethoxy-4--2'-oxospiro[cyclohexane-1,3'-indol]-1'-yl]sulfonyl}-3-methoxybenzamide (en) |
| dbp:n |
3 (xsd:integer) |
| dbp:o |
8 (xsd:integer) |
| dbp:pubchem |
9810773 (xsd:integer) |
| dbp:s |
1 (xsd:integer) |
| dbp:smiles |
C1COCCN1CCO[C@H]2CC[C@]3c4ccccc4NSc5cccCNCC (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
QKXJWFOKVQWEDZ-VCCCEUOBSA-N (en) |
| dbp:unii |
AJS8S3P31H (en) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
455169440 (xsd:integer) |
| dbp:watchedfields |
changed (en) |
| dbp:width |
200 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Stdinchicite dbt:Cardiovascular-drug-stub dbt:Oxytocin_and_vasopressin_receptor_modulators |
| dcterms:subject |
dbc:Diuretics dbc:Tert-butyl_compounds dbc:Vasopressin_receptor_antagonists |
| gold:hypernym |
dbr:Antagonist |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Agent109190918 yago:Agent114778436 yago:CausalAgent100007347 yago:DiureticDrug103214670 yago:Drug103247620 yago:Matter100020827 yago:PhysicalEntity100001930 yago:WikicatHormonalAgents dbo:Drug yago:Substance100020090 yago:WikicatDiuretics |
| rdfs:comment |
Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites. Development was discontinued in 2009. (en) Satavaptan (Nome in codice dello sviluppo SR121463, ex marchio provvisorio Aquilda) è un antagonista del recettore della vasopressina-2 che è stato scoperto dalla Sanofi-Aventis ed era in fase di sviluppo per il trattamento dell'iponatremia. È stato anche studiato per il trattamento dell'ascite. Lo sviluppo è stato interrotto nel 2009. (it) |
| rdfs:label |
Satavaptan (it) Satavaptan (en) |
| owl:sameAs |
freebase:Satavaptan wikidata:Satavaptan dbpedia-fa:Satavaptan dbpedia-it:Satavaptan dbpedia-sh:Satavaptan dbpedia-sr:Satavaptan https://global.dbpedia.org/id/4vAei yago-res:Satavaptan |
| prov:wasDerivedFrom |
wikipedia-en:Satavaptan?oldid=997782188&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Satavaptan_structure.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Satavaptan |
| is dbo:wikiPageRedirects of |
dbr:C33H45N3O8S dbr:Aquilda |
| is dbo:wikiPageWikiLink of |
dbr:Vasopressin_receptor_antagonist dbr:C33H45N3O8S dbr:Aquilda dbr:Vasopressin_receptor dbr:Vasopressin_receptor_2 dbr:List_of_drugs:_S–Sd |
| is foaf:primaryTopic of |
wikipedia-en:Satavaptan |
